FDA授予dostarlimab-gxly加速批准,用于dMMR晚期实体瘤
正文 · 中文译文
FDA授予多斯塔利单抗-gxly加速批准用于dMMR晚期实体瘤 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已证实临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2021年8月17日,美国食品药品监督管理局(FDA)授予多斯塔利单抗-gxly(Jemperli,GlaxoSmithKline LLC)加速批准,用于经FDA批准的检测确定为错配修复缺陷(dMMR)的复发或晚期实体瘤成人患者,这些患者在既往治疗后或之后出现疾病进展,且无满意的替代治疗选择。 今日,FDA还批准了VENTANA MMR RxDx Panel作为伴随诊断器械,用于筛选dMMR实体瘤患者接受多斯塔利单抗-gxly治疗。 多斯塔利单抗的疗效在GARNET试验(NCT02715284)中进行了评估,该试验是一项非随机、多中心、开放标签、多队列试验。疗效人群包括209例dMMR复发或晚期实体瘤患者,这些患者在系统治疗后出现疾病进展,且无满意的替代治疗。 主要疗效终点为总缓解率(ORR)和缓解持续时间(DoR),由盲法独立中心审查根据RECIST 1.1确定。ORR为41.6%(95% CI:34.9,48.6),其中完全缓解率为9.1%,部分缓解率为32.5%。中位DOR为34.7个月(范围2.6,35.8+),95.4%的患者持续时间≥6个月。 dMMR实体瘤患者最常见的不良反应(≥20%)为疲乏/乏力、贫血、腹泻和恶心。最常见的3级或4级不良反应(≥2%)为贫血、疲乏/乏力、转氨酶升高、脓毒症和急性肾损伤。免疫介导的不良反应也与dostarlimab-gxly相关,包括肺炎、结肠炎、肝炎、内分泌病、肾炎和皮肤毒性。 dostarlimab推荐剂量为第1至第4次给药500 mg,每3周一次,静脉输注30分钟以上。第4次给药后3周开始的后续给药为1,000 mg,每6周一次。 查看Jemperli完整处方信息。 本适应证基于肿瘤缓解率和缓解持久性获得加速批准。本适应证的持续批准可能取决于确证性试验中对临床获益的验证和描述。 本审评使用了评估辅助工具(Assessment Aid),这是申请人自愿提交以促进FDA审评的材料。 本申请获得优先审评资格。FDA加速计划的描述见《行业指南:严重疾病药物和生物制品的加速计划》。 医疗保健专业人员应将所有怀疑与使用任何药物和器械相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 对于研究性肿瘤产品的单患者 IND 申请协助,医疗保健专业人员可致电 240-402-0004 联系 OCE 的 Project Facilitate,或发送电子邮件至 OncProjectFacilitate@fda.hhs.gov。 有关 COVID-19 大流行的信息,请参阅以下资源: FDA:Coronavirus Disease 2019 (COVID-19) NCI:Coronavirus: What People With Cancer Should Know CDC:Coronavirus (COVID-19) 在 Twitter @FDAOncology 上关注肿瘤卓越中心。 内容更新日期: 07/18/2023 受监管产品 药品 肿瘤学
正文 · 英文原文
FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. Today, the FDA also approved the VENTANA MMR RxDx Panel as a companion diagnostic device to select patients with dMMR solid tumors for treatment with dostarlimab-gxly. The efficacy of dostarlimab was evaluated in the GARNET Trial (NCT02715284), a non-randomized, multicenter, open-label, multi-cohort trial. The efficacy population consisted of 209 patients with dMMR recurrent or advanced solid tumors who progressed following systemic therapy and had no satisfactory alternative treatment. The primary efficacy endpoints were overall response rate (ORR) and duration of response (DoR) as determined by blinded independent central review according to RECIST 1.1. The ORR was 41.6% (95% CI: 34.9, 48.6), with 9.1% complete response rate and 32.5% partial response rate. Median DOR was 34.7 months (range 2.6, 35.8+), with 95.4% of patients with duration ≥6 months. Most common adverse reactions (≥20%) in patients with dMMR solid tumors are fatigue /asthenia, anemia, diarrhea, and nausea. Most common Grade 3 or 4 adverse reactions (≥2%) were anemia, fatigue/asthenia, increased transaminases, sepsis, and acute kidney injury. Immune-mediated adverse reactions are also associated with dostarlimab-gxly including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and dermatologic toxicity. The recommended dostarlimab dosage is 500 mg every 3 weeks for dose 1 through 4, as an intravenous infusion over 30 minutes. Subsequent dosing beginning 3 weeks after dose 4 is 1,000 mg every 6 weeks. View full prescribing information for Jemperli. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was granted priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncology. Content current as of: 07/18/2023 Regulated Product(s) Drugs Oncology